VTYX
HealthcareVentyx Biosciences, Inc.
$7.82
$-0.58 (-6.90%)
Jan 5, 2026
Price History (1Y)
Analysis
Ventyx Biosciences, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $558.02M and 83 employees. The industry classification aligns with the company's focus on research and development in its field. Financially, Ventyx Biosciences has reported significant net income and EBITDA losses, totaling -$106,607,000 and -$116,438,000, respectively, over the trailing twelve months. Additionally, the free cash flow during this period was -$47,460,248, while the company holds $192.64M in cash against a debt of $10.02M. The margins for gross profit, operating income, and net income are all at 0.0%. Returns on equity and assets were -45.4% and -28.5%, respectively, while the debt to equity ratio is 5.24. The valuation metrics indicate a negative forward P/E of -4.87 and an EV/EBITDA of -3.58, suggesting that the company's performance has been below expectations in recent periods. The price-to-book ratio is 2.91, which may provide some context for assessing the company's value relative to its assets. The beta of 1.24 indicates a moderate level of volatility compared to the market as a whole.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $558.02M
- P/E Ratio
- N/A
- 52-Week High
- $10.55
- 52-Week Low
- $0.78
- Avg Volume
- 4.39M
- Beta
- 1.24
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 83